FDA Off-Label Policy Under Fire: Court Rulings Pile Up, House E&C Floats New Bill
Republican leadership on the House Energy and Commerce Committee is reviving efforts to legislate changes to FDA’s off-label policy. That renewed pressure comes as the courts are increasingly challenging FDA’s ability to bar truthful speech about unapproved indications.
You may also be interested in...
Merck wasn’t as quick to the COVID vaccine race as some others, but it believed that its use of ‘proven platforms’ would win out in the end. Not anymore.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.